March 16, 2020

Latest Iteration of Global Program Will Identify Promising Myopia & Presbyopia Concepts

SAN RAMON, Calif., March 16, 2020—CooperVision is now accepting submissions for its 2020 Science and Technology Awards program, with a focus on novel research concepts to address myopia and presbyopia. The program fosters partnerships between recipients and CooperVision scientists to explore new dimensions in vision care, with the goal of translating innovative ideas into practical solutions.

“Since launching the Science and Technology Awards in 2014, multiple collaborations have emerged that are helping shape advancements in contact lenses, refractive error and ocular disease,” said Francis Erard, CooperVision’s Vice President of Research & Development. “We have high expectations for new partnerships this year, especially with such high-visibility areas as myopia and presbyopia.”

Over its history, the program has made 14 grants totaling $2 million to investigate matters such as ocular surface health, contact lens discomfort, contact lens functionality, and retinal response to optical defocus.

In 2020, submissions will be considered for the following subjects:

  • Strategies and interventions to slow myopia progression, with an emphasis on new technologies for treatment and management; effective solutions for fast progressors; understanding environmental factors that may initiate and prolong progression; and intelligent systems and data approaches for identifying at-risk eyes.
  • Technologies to enhance the optical functionality of contact lenses for the correction of presbyopia.

Proposals may span proof-of-concept through translational stages and are eligible for two types of awards. The CooperVision Seedling Award is intended for investigation of early stage concepts for a one-year period, with a maximum grant of $100,000. The CooperVision Translational Research Award is a two-year grant for substantive projects with funding up to $400,000. It is intended to incentivize collaboration with CooperVision in new research areas.

CooperVision Science and Technology Awards are open to any researcher with principal investigator (PI) status holding an OD, MD, PhD or equivalent degree. Applicants such as postdoctoral fellows with a waiver of PI status must submit appropriate documentation before funding can be disbursed.

Interested applicants must submit a letter of intent before May 31, 2020. If a letter is accepted, an applicant will be invited to submit a full proposal. Additional information and the online application are available at

# # #

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit

Media Contact
Mike McDougall, APR, Fellow PRSA, McDougall Communications or +1-585-434-2150